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Abstract 
Antisense oligodeoxynucleotides (ODNs) are short synthetic DNA polymers 
complementary to a target RNA sequence. They are commonly designed to halt a 
biological event, such as translation or splicing. ODNs are potentially useful therapeutic 
agents for the treatment of different human diseases. Carbohydrate-ODN conjugates have 
been reported to improve the cell specific delivery of ODNs through receptor mediated 
endocytosis. We have tested the anti-HIV activity and biochemical properties of the 5’-end 
glucose-conjugated GEM 91 ODN targeting the initiation codon of the gag gene of HIV-1 
RNA in cell-based assays. The conjugation of a glucose residue significantly reduces the 
immunostimulatory effect without diminishing its potent anti-HIV-1 activity. No significant 
effects were either observed in the ODN stability in serum, in vitro degradation of 
antisense DNA-RNA hybrids by RNase H, cell toxicity, cellular uptake and ability to 
interfere with the HIV-1 genome dimerisation. 
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Introduction 
There is considerable pharmaceutical interest in the use of synthetic antisense 
oligodeoxynucleotides (ODNs) to specifically interfere in the process of gene expression.[1] 
Antisense ODNs are short synthetic DNA polymers (or chemical analogues) that are 
complementary to a target RNA molecule. They are designed to halt a biological event, 
such as translation or splicing.[2] Antisense ODNs have been pursued as a major class of 
new pharmaceuticals for a variety of human diseases, including cancer and viral 
infections.[3] After several decades of research and development, so far very few nucleic 
acid therapeutics have been approved for human use: Fomivirsen (Vitravene) is an 
antisense ODN composed of 21 phosphorothioate-linked nucleosides which was approved 
for the treatment of retinal inflammation caused by cytomegalovirus, but it was later 
withdrawn from the market.[4] Similarly Macugen (pegaptanib sodium injection), a 28-
nucleotide RNA aptamer conjugated to 20 kDa polyethylene glycol targeted to heparin 
binding domain of VEGF165, was approved for the treatment of wet age-related macular 
degeneration.[5] Recently, the US Food and Drug Administration has approved a new lipid-
lowering drug: Mipomersen (marketed as Kynamro by Genzyme, Cambridge, MA, USA). 
This drug is an antisense molecule based on 2′-O-(2-methoxy) ethyl–modified ribose ODN 
developed against ApoB100 mRNA to treat the homozygous familial 
hypercholesterolemia.[6] However, the clinical success achieved so far with ODNs has not 
been satisfactory; some of the major impediments have been recognised as their instability 
against nucleases, poor delivery or uptake by cell targeted, and off-target effects or toxicity 
among others. To address these limitations, a variety of different chemical modifications in 
the ODN backbone have been introduced. ODNs are quickly degraded by nucleases in 
both in vitro and in vivo contexts, increasing their nuclease resistance is a major issue for 
the development of ODN based in vivo applications. They can be degraded by both endo- 
and exonucleases.[7] One of the most straightforward modifications made to an ODN to 
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increase the resistance to nuclease degradation, is to replace a non-bridging oxygen on 
the phosphate backbone with sulphur, producing a phosphorothioate (PS) linkage[8] 
(Figure 1B). It has been later learned that RNA/DNA hybrids containing this modification 
are also substrate for RNase H,[9] which has been shown to be the molecular inhibition 
mechanisms of many antisense ODN by promoting the degradation of the target RNA. 
Methylation of the 2’ position of the ribose (2’-OMe) is already a standard modification to 
yield highly nuclease resistant ODNs.[10] Numerous efforts have also been made to 
improve the pharmacokinetic and pharmacodynamic properties of antisense ODNs, and 
very importantly to overcome negative or undesired effects by covalently attaching, 
conjugating, chemical groups or molecules that may provide new properties to the 
ODNs.[11] The potential application of conjugated ODNs is not only limited to therapeutics 
but also in diagnostics and nanotechnology. Conjugation of ODNs with cationic 
compounds, such as poly-(L)-lysine[12] or polyamides,[13] lipophilic conjugates, such as 
cholesterol,[14] attachment of long chain alcohols,[15] phospholipids,[16] aromatic 
compounds,[17] as well as polyethylene glycol[18] have been successfully tested to pursue a 
more efficient ODNs delivery to specific target cells which represent an important limitation 
of in vivo ODN application. We have previously reported an improvement in the cell uptake 
of ODNs containing a terminal glucose unit linked through a long tetraethylene glycol 
spacer or just one doubler dendrimer in HeLa and U87-CD4+-CXCR4+ human cells.[19] 
Such modifications also contribute to the stability of oligoribonucleotides against 5’-end 
exonuclease degradation.[20]   
The phosphorothioate antisense ODN GEM 91[21], registered as trecovirsen, 
complementary to the initiation codon of the gag ORF of the HIV-1 RNA (positions 324-
348)[22] (Figure 1A) was shown to yield a potent anti-HIV activity in cell culture.[21,23] 
Surprisingly, a transient increase in HIV-1 replication was reported in vivo when GEM 91 
was administered by continuous i.v. infusion for 8 days in a blinded dose escalation 
 5
study.[24] To test whether this was a side-effect induced by the CpG-like motifs present in 
the GEM 91 ODN, a new antisense ODN (GEM 92) lacking these motifs was assayed. 
GEM 92 ODN resulted in a loss of this viral replication enhancement induced in vivo by the 
GEM 91, but exhibited an unacceptable anti HIV-1 activity.[25] This result is in good 
agreement with those previous observations that ODNs containing CpG motifs mimic 
properties of bacterial CpG DNA activating immune response through TLR9 (Toll-like 
receptor 9)[26] and that the TLR9 ligand (CpG DNA in that study) promotes the HIV 
replication in ex vivo HIV-1 transgenic mouse spleen cells.[27] Therefore, it is possible that 
an increase in HIV-1 copy number following administration of GEM 91 was due to 
activation of TLR9.  
In the current work we have analysed the biological properties and anti-HIV-1 activity of 
the conjugation of a glucose residue at the 5’-end of the GEM 91 (Gluc-GEM 91) resulting 
in a significant reduction of the immune response activation while maintaining its antiviral 
activity and biochemical properties. 
 
 
Results 
Stability of 5’ glucose conjugated ODNs in serum 
To analyse whether ODNs modified at the 5’-end by glucose are protected from nuclease 
digestion the stability of phosphorothioate (PS) and phosphodiester (PO) ODNs 5’ glucose 
conjugated (Gluc-ODN) in cell culture media containing 10% heat inactivated FBS were 
compared with its parental nonconjugated ODNs. Results shown in figure 2 indicate that 
while the PS ODN derivatives, GEM 91 (PS) and Gluc-GEM 91 (PS), remained intact after 
144 h, the  GEM 91 (PO) and Gluc-GEM 91 (PO) exhibited a half life of around 120 min 
and were completely degraded within 240 min of incubation. As expected the 
phosphorothioate substitution yielded highly resistant serum nucleases ODNs. However, 
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conjugating of a glucose molecule to the 5’-end of the ODNs did not diminish their serum 
stability. 
 
RNase H digestion of 5’ glucose conjugated ODN/RNA hybrids 
RNase H mediated degradation of ODN/RNA hybrids has been shown to be a key event in 
the inhibitory molecular mechanism of many antisense ODNs. However, residue 
modifications could affect the ability of an ODN to trigger RNase H mediated degradation 
of RNA following hybrid formation. To analyse the effect of the 5’ glucose conjugation of 
ODNs (Gluc-ODN) in RNase H digestion, an internally 32P-labelled HIV-1 RNA fragment 
containing the first 357 nt of the HIV-1 genomic RNA was synthesized in vitro and 
subjected to RNase H digestion in the absence or presence of different concentrations of 
unlabelled antisense ODNs (Figure 3). The predicted RNase H cleavage product (325 nt) 
was detected in the presence of the ODN GEM 91 (PO) or Gluc-GEM 91 (PO) at 
concentrations as low as 0.01 µM, and leading intact HIV-1 5’-UTR RNA to undetectable 
levels after incubation of 30 min in the presence of 0.1 µM of either ODN. Similarly, RNase 
H digestion of the HIV-1 RNA was completed in the presence of 1 µM GEM 91 (PS) or 
Gluc-GEM 91 (PS). No difference in the RNase H digestion efficiency was observed 
between GEM 91 (PO) and Gluc-GEM 91 (PO) or GEM 91 (PS) and Gluc-GEM 91 (PS) 
ODNs. This implies that the presence of the glucose molecule in the 5’-end does not 
interfere either with the ODN-RNA hybridisation process or with the RNase H digestion. 
 
Interference of the HIV-1 RNA dimerisation by glucose conjugated ODNs  
Previous results had shown that the target region of GEM 91 is involved in HIV-1 genomic 
RNA dimerisation.[28] Therefore, Gluc-ODNs were tested for their ability to interfere with 
the HIV-1NL4-3 5’-UTR RNA dimerisation (Figure 4). Under low ionic strength conditions no 
dimers were detected (Figure 4; Monomer control). In contrast, under high ionic strength 
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conditions ~88% of the 1–357 HIV-1NL4-3 5’-UTR genomic RNA fragment folded into a 
dimer conformation (Figure 4; Dimer control). The presence of the GEM 91 (PO) and Gluc-
GEM 91 (PO) resulted in the reduction of dimer formation (49% and 53% dimer, 
respectively; Figure 4; lanes 5 and 6). However, poor inhibition was observed with GEM 91 
(PS) and Gluc-GEM 91 (PS) (70% and 73% dimer yield, respectively; Figure 4; lanes 7 
and 8). As expected, no inhibition of dimerisation was observed in the presence of the 
control ODNs pLCX-25 and Random-25 (Figure 4; lanes 3 and 4). The relative 
dimerisation rates of all tested ODNs, conjugated and noconjugated, were significantly 
different from the control, as determined by one-way ANOVA analysis (p < 0.001). No 
significant difference in the dimerisation efficiency was observed between GEM 91 (PO) 
and Gluc-GEM 91 (PO). Similar effects were seen between GEM 91 (PS) and Gluc-GEM 
91 (PS) ODNs. It is clear that the phosphorothioate modification slightly decreases the 
relative binding affinity compared with natural phosphodiester ODNs (Figure 4; compare 
lanes 5 and 6 to lanes 7 and 8), in agreement with the lower melting temperature of the 
ODN (PS)-RNA duplex relative to the ODN (PO)-RNA duplex.[29] In addition these results 
also indicated that the presence of a glucose molecule covalently linked to the 5’-end of 
the GEM 91 ODN (PO or PS) did not modify its ability to interfere with the HIV-1 genomic 
dimerisation process.  
 
Anti-HIV-1 activity of 5’ glucose conjugated ODNs 
The effect of the 5’ glucose conjugation in the antiviral activity of the GEM 91 (PS) was 
tested using two different experimental strategies. Firstly, human glioblastoma U87-CD4+-
CXCR4+ cells were cotransfected with 500 pmol (1 µM) of ODN and 100 ng of pNL4-3 
plasmid, which contains a full infectious provirus, HIV-1NL4-3.[30] Viral particles production 
was measured at two days post-transfection as p24 antigen abundance in the cellular 
supernatant as described in Experimental Section. This represents an experimental model 
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of a post-integrative viral inhibition assay. No viral particles were detected in the cell 
cultures transfected with either of the phosphorothioate modified ODN; GEM 91 (PS) or 
Gluc-GEM 91 (PS) (Figure 5A). These potent inhibitions are consistent with the previously 
reported data.[21,23] Similarly, a highly efficient inhibition was seen in the presence of GEM 
91 (PO) or Gluc-GEM 91 (PO) (86 and 84% inhibition, respectively). Potent inhibition was 
also observed at an ODN concentration as low as 0.02 μM (data not shown).  
Secondly, ODNs were tested for their ability to inhibit HIV-1 replication in a viral pre-
integrative model. For this purpose HIV-1 infected U87-CD4+-CXCR4+ cell cultures were 
treated with 1 µM ODN and p24 antigen was measured as described in Experimental 
Section. A potent HIV-1 particles production inhibition was observed with GEM91 (PS) 
(90% inhibition) and the glucose conjugated derivative Gluc-GEM 91 (PS) (91% inhibition) 
(Figure 5B). However, little inhibitory effect was observed in GEM 91 (PO) and Gluc-GEM 
91 (PO) (10% and 20% inhibition, respectively). Cell infection was also qualitatively 
monitored by microscopy as syncytium formation (Figure 6). HIV-1 infected glioma cells 
fuse to form multinuclear cell aggregates (syncytia), followed by cell death and eradication 
of monolayer cultures. In contrast to infected cell culture treated with GEM 91 (PO), Gluc-
GEM 91 (PO) or control ODNs, no syncytia was observed in those treated with GEM 91 
(PS) or Gluc-GEM 91 (PS) (Figure 6) confirming the results obtained measuring p24 
antigen (Figure 5B). We further examined the effects of different ODNs on the cell viability 
in order to determine their toxicity. Cell viability was determined by trypan blue exclusion 
assay after 1-5 days post-transfection. No significant reduction of cell viability was 
observed at ODN concentrations up to 1 μM (data not shown). 
 
Long-term protection against HIV-1 infection in Jurkat cells by Gluc-GEM 91 (PS) 
To compare the long-term efficacy of GEM 91 (PS) with that of Gluc-GEM 91 (PS), 
infected Jurkat cells were maintained at concentration of 1, 2, 4 or 8 μM of GEM 91 (PS) or 
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Gluc-GEM 91 (PS) respectively. The level of HIV-1NL4-3 replication was monitored 
throughout the time by assaying p24 levels (Figure 7). Maximum inhibition was observed 
after day six of ODN treatment for all the concentrations assayed, yielding inhibitions near 
95% for the highest ODN concentrations tested. At day 10, the level of p24 antigen was 
below (5-25%) compared to the control HIV-1NL4-3 infected Jurkat cells. This high inhibition 
was maintained up to day 20 (80-85% inhibition) for cell cultures treated with the highest 
doses of ODNs (4 or 8 μM). No significant differences were observed between cells 
treated with GEM 91 (PS) and Gluc-GEM 91 (PS) ODNs.   
 
Conjugation of glucose at the 5’-end of GEM 91 does not increase cellular uptake 
In order to examine whether the glucose conjugation increased the cellular ODN uptake, 
we compared the cellular uptake of 3’ end 32P labelled Gluc-GEM 91 (PS) with the 
unconjugated control. ODNs were added to human cells HEK 293T or U87-CD4+-CXCR4+ 
cells in culture and incubated for 2, 4 and 8 h. At each time point, the cells were treated 
with DNase I, removed from the dishes with trypsin and washed with PBS as described in 
Experimental Section. The total amount of 32P labelled ODN taken up by cells was 
quantified. No significant changes in Gluc-GEM 91 (PS) and GEM 91 (PS) uptake at 2, 4 
or 8 h were observed (Figure 8 and data not shown). Throughout the ODN incubation 
there is nearly a linear increase of total cellular ODN uptake. This result indicates that the 
glucose residue at the 5′-end does not result in an improvement of the penetration of the 
ODN through the cellular membrane. 
 
The 5’ glucose conjugation diminished the intrinsic CpG ODNs immunoestimulatory 
effect  
An additional limitation associated to the use of ODNs is the nonspecific stimulation of the 
immune response, which may result in undesired cytotoxic effects challenging their in vivo 
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applications. In particular synthetic ODN containing unmethylated cytosine-guanosine 
motifs (CpG) have been described as potent immunoestimulatory.[31] It is important to note 
that GEM 91 ODN contains a CpG dinucleotide located closer to the 5’-end and it has 
been shown that such dinucleotide located closer to the 5’-end is critical for induction of 
the immune responses[32] and the blockage of the ODN 5′ end results in loss of the 
immunostimulatory effect.[33] To determine the effect of the conjugation of the glucose 
molecule to the 5’-end of GEM 91 in the stimulation of the innate immune response, we 
directly quantified the amount of IL-10 mRNA expression by real time quantitative RT-
PCR. For this purpose human Namalwa cells, which has been shown to express IL-10 in 
response to CpG ODNs, were used.[34]  IL-10 mRNA amount was 50 and 40 fold higher in 
the Namalwa cells treated with the immunostimulatory OD2006 (used as positive control) 
and the Gluc-GEM 91, respectively, than in untreated cells (Figure 9). In contrast, cell 
treatment with Gluc-GEM 91 (PS) resulted in a 87.2% decrease of IL-10 mRNA level 
expression compared to cells treated with GEM 91 (PS). These results indicate that 
blockage of the 5’-end with a glucose results in a decrease of the TLR9-mediated ODN 
immunostimulatory activity in accordance with previous data.[33] 
 
 
Discussion 
A potent antisense drug should be highly resistant to nucleases, to exhibit high affinity for 
the target mRNA and favourable pharmacokinetics. These properties can be achieved by 
the introduction of chemical modifications. Most of the ODNs being used now in clinical 
trials contain a phosphorothioate or morpholino backbone instead of the phosphodiester. 
Additionally, chemical conjugation or linking reporter groups to ODNs has tremendous 
therapeutic potential not only to improve the existing antisense ODN biological properties 
but also to impart entirely new ones. Diverse reporter groups like peptides, vitamins, 
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hormones, growth factors, enzymes, carbohydrates, lipophilic molecules, polymers, 
fluorescent dyes, luminescent groups, spin labels, metal complexes and nanoparticles 
have been conjugated to ODNs to obtain conjugates for various applications. Many 
synthetic carbohydrate-ODN conjugates have been synthesized, but most of them have 
not yet been evaluated in cell-based assays.[35] Information on the stability of ODNs, and 
their structurally modified analogues, in the biological milieu is important not only for cell 
culture studies but also, from a pharmaceutical viewpoint, in designing effective delivery 
systems for ODNs as therapeutic agents.  
Natural phosphodiester ODNs are quickly digested by nucleases, it appears that the bulk 
of biologically significant nucleolytic activity in serum is 3’ exonuclease,[7b] however within 
the cell nucleolitic activity is both 3’ and 5’ exonuclease.[7a] As expected, our results 
indicated that in cell culture medium containing heat inactivated serum GEM 91 (PS) and 
Gluc-GEM 91 (PS) were more stable than GEM 91 (PO) and Gluc-GEM 91 (PO). We 
found no differences in stability between the glucose conjugated and unconjugated ODNs 
in serum. However, these ODNs attached to glucose in its 5'-end could be even more 
stable in vivo than unconjugated ODNs since modification at the 5’-end may protect them 
from 5’ exonuclease digestion in vivo. Our results also indicated that the 5’ glucose 
conjugation did not lead to an improvement of the ODN cellular uptake (Figure 8). These 
results mostly agree with previous observations reporting that cellular uptake was hardly 
improved by the conjugation of glucose monomers just when linked through a long 
tetraethylene glycol spacer, [19] showing that a 15 to 18 atoms distance between the 
glucose and the ODN should be kept to achieve a more efficient cellular internalization. 
This observation should be considered for further optimization of antisense Gluc-ODNs. 
The antiviral activity of GEM 91 (PO), Gluc-GEM 91 (PO), GEM 91 (PS) and Gluc-GEM 91 
(PS) was tested in acutely HIV-1 infected cells using two different CD4+ cell lines, Jurkat 
and U87-CD4+-CXCR4+, which are susceptible to HIV-1 infection and allow a high level of 
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viral replication. Our results showed that in contrast to the PS derivatives, the GEM 91 
(PO) and Gluc-GEM 91 (PO) exhibited antiviral activity only when they are delivered by 
transfect agents to culture cells (Figure 5A). The most likely explanation is that GEM 91 
(PO) and Gluc-GEM 91 (PO) are not resistant enough in the cell or the culture medium 
and the potential problem of nuclease degradation of the ODNs may conceivable be 
overcome by delivering them using transfection agents, entering within the nucleus more 
efficiently and therefore resulting in significant inhibition of viral particles production. It is 
remarkable that the conjugation of glucose at the 5′-end of GEM 91 (PS) or GEM 91 (PO) 
resulted in similar anti HIV-1 activity to that of its unconjugated molecule, indicating that 
the glucose residue at the 5′-end does not result in a modification of the mechanism of 
action of the ODNs challenging their antiviral activity. The lack of correlation between the 
in vitro dimerisation effects and the anti-HIV activities in cell culture assays clearly indicate 
that the latest is mainly due to the ODNs interference with other steps of the HIV-1 
particles production process. ODNs cell induced toxicity is also an important factor that 
could lead to an overestimation of the antiviral ODN effect when assessing it by a p24 
assay. In the conditions used in this study we have not detected any cytotoxicity as 
monitored by trypan blue dye exclusion (data not shown). 
Previous studies have demonstrated that differences in immunostimulatory activity of 3′- 
and 5′-conjugates are due to the requirement of 5′-end accessibility for TLR9-mediated 
immune responses, but not as a result of their differences in cellular uptake, as both types 
of conjugates are taken up by cells to the same extent.[33] Further, these studies showed 
that conjugation of a mono, di, tetra, or oligonucleotide through 5′-5′ linkage or a 
fluorescein moiety, but not a phosphorothioate group, at the 5′-end significantly reduces 
TLR9-mediated immune response.[33] These results together with our present study 
suggest that an accessible 5′-end of ODN is required for TLR9- mediated immune 
responses and conjugation of moieties like peptides or glucose at the 5′-end of ODN 
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results in loss of TLR9-mediated immune responses. On the other hand, it is likely that 
TLR9 activated immune response by the CpG motif in GEM 91 was responsible for the 
observed increases in viral load,[24] being biologically active even in ODN (PS). Our data 
clearly indicate that conjugation of glucose to the 5’-end of GEM 91 (Gluc-GEM 91) 
decreases immune response through TLR9 while it is taking up well by cells, hybridizes to 
its complementary nucleic acid target and maintain an unaffected anti HIV-1 activity. 
Presently several antisense ODN (PS) containing CpG motifs are in human clinical trials 
for various diseases and indications. Our data suggests that conjugation of a molecule of 
glucose at the 5’-end could act as “immunosupressor” and thereby reduce toxic effects 
while still allowing proper binding to its target sequence, and biological activity.  
In conclusion, the results presented here demonstrate that the 5’ Gluc-ODN conjugation 
decreases the innate cellular response associated to the recognition of the 5’-end in CpG 
ODNs, and therefore the undesired side effects associated to such response, at the time 
that does not interfere with the biological activity of the ODNs, proposing these conjugates 
are of value as antisense agents. 
 
 
Experimental Section  
ODNs and RNA synthesis 
All ODNs were synthesized on 1 μmol scale using standard phosphoramidite chemistry. 
GEM 91 ODN series used in this study were: GEM 91 (PO) 5’-
CTCTCGCACCCATCTCTCTCCTTCT-3’, which corresponds to the unmodified ODN; 
Gluc-GEM 91 (PO), contained a glucose molecule covalently linked to its 5’-end; GEM 91 
(PS) and Gluc-GEM 91 (PS) are the corresponding totally substituted phosphorothioate 
ODNs. The 5’ glucose conjugation was obtained as previously described.[36] The Random-
25 ODN, a 25 nt long random sequence, and pLCX-25 (5’-
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GACGTCGAGTGCCCGAAGGATAGCT-3’) a 25 nt long ODN which is not complementary 
to any known cellular or HIV-1 gene, were used as negative controls. The DNA template 
for the synthesis of the HIV-1 5’-UTR genomic RNA fragment was obtained by PCR 
amplification of the pNL4-3 plasmid,[30] using the primers 5’-T7pNL4-3: 5’-
TAATACGACTCACTATAGGGTCTCTCTGGTTAG-3’ (T7 promoter sequence is indicated 
in bold), and 3’ pNL4-3-gag 5’-GCTTAATACCGACGCTCTC-3’. HIV-1 5’-UTR genomic 
RNA fragment was obtained by in vitro transcription as previously described.[37]  
 
Antisense ODN stability assay 
A total of 3 nmol of each ODN were resuspended in of 30 μL sterile ddH2O and incubated 
with 70 μL Dulbecco´s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) at 37ºC. Aliquots of 10 μL were withdrawn at each time point, added 
to a mix of 2 μL of 10X TE and 10 μL of 2X loading buffer (0.1%  bromophenol blue, 1.2X 
TBE and 10%, glycerol), and snap-frozen on dry ice immediately. Samples were thawed 
and run on a 15% nondenaturing 1X TBE polyacrylamide gel at 100 V for 75 min and 
stained with a 1:10000 dilution of GelStar® Nucleic Acid Gel Stain (Lonza, Rockland, ME) 
in 1X TBE buffer for 30 min. Gels were scanned using Typhoon 9400 
Phosphorimager/Fluorescence Imager and quantified with Image Quant software 5.2© (GE 
Healthcare; Chalfont ST. Giles, UK). 
 
In vitro RNase H cleavage assay 
RNase H digestion assays were essentially as described in Reyes-Darias et al. (2012).[28b] 
Viral RNA transcript was incubated separately with each different concentrations of each 
ODN for 30 min at 37°C. Subsequently, 5 U of RNase H was added to the mixtures and 
incubated at 37°C for 20 min. The reactions were quenched with equal volumes of 2X 
formamide loading buffer and loaded onto a 7 M urea 6% polyacrylamide denaturing gel in 
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1X TBE buffer. Electrophoresis was followed at 20 mA for approximately 90 min, and gels 
were dried and analysed as described above. 
 
Inhibition of HIV-1 RNA dimerisation by ODNs 
HIV-1 RNA dimerisation reactions were performed as previously described[38] in the 
presence or absence of 100 pmol of unlabelled antisense ODN. Samples were resolved in 
1% agarose gels in 1X TBM buffer (0.5X Tris–borate, 0.1 mM MgCl2), and gels were 
visualized and quantified as described above. The dimerisation efficiency was calculated 
as [dimmer x 100/(dimer + monomer)]. Data are expressed at the mean ± standard 
deviation of two independent experiments. 
 
Cell culture 
The human glioblastoma U87-CD4+-CXCR4+ cell line, stably expressing CD4 and the 
chemokine receptor CXCR4, was grown in DMEM supplemented with 10% FBS, 50 μg/mL 
gentamycin (Sigma Chemical Co. St Louis, MO), 1 mM sodium pyruvate (Sigma), 2 mM L-
glutamine (Sigma), 300 μg/mL G418 (Sigma) and 1 μg/mL puromycine (Sigma). The 
human embryonic kidney HEK 293T cell line was maintained in DMEM supplemented with 
10% FBS, 100 μg/mL streptomycin (Sigma), 4 mM L-glutamine and 1 mM sodium 
pyruvate. Human Burkitt lymphoma cell line Namalwa was maintained as suspension 
culture in RPMI 1640 medium supplemented with 10% FSB, 2 mM L-glutamine and 50 
μg/mL gentamycin (Sigma). Cells were maintained at 37ºC in a humidified atmosphere 
with 5% CO2.  
 
HIV-1 inhibition of viral particles production assays 
For post-integrative viral inhibition assay U87-CD4+-CXCR4+, 1x105 cells/well were 
seeded in 0.5 mL of DMEM in 24-well culture plates and incubated at 37°C for 24 h before 
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co-transfection. The following day cells were co-transfected with 500 pmol (1 µM) of ODN 
and 100 ng of pNL4-3 plasmid complexed together with 1 μL Fugene HD (Roche; 
Mannheim, Germany). After 6 hours, the transfection mixture was replaced with 1 mL of 
fresh growth medium, and cells were further incubated at 37°C for two days before p24 
determination. 
For pre-integrative viral inhibition assays, U87-CD4+-CXCR4+ cells were seeded in 0.5 ml 
of DMEN at a density of 8x105 cells/well in 24-well culture plates and incubated at 37°C for 
24 hours before infection. Cells were infected by the addition of 0.4 ng of p24 HIV-1 type 
pNL4-3 in a total volume of 200 µL of medium. After 3 hours incubation at 37ºC, cells were 
washed and treated with the individual ODN at 1 μM concentration. HIV-1 replication was 
monitored after five days at the cellular level by syncytia formation by light microscopy and 
viral p24 antigen in 200 µL culture supernatants using the Greenscreen HIV-1 Ag Enzyme 
Immunoassay (EIA; Bio-Rad, Hercules, CA) following manufacturer instructions. 
Alternatively, Jurkat cells (5x105/mL) were infected under the same conditions for long 
term antiviral assays. Infected cells were treated with GEM 91 and Gluc-GEM 91 at 
concentrations 1, 2, 4 and 8 μM, and split into separate flasks with fresh medium to 5x105 
cells/mL every 3 or 4 days. The p24 antigen levels in the supernatant were quantified at 
the indicated times. Cell viability was detected by trypan blue exclusion assay. The 
percentage of viable cells is calculated at different days after transfection.  
Virus stocks for infection were produced by transfection of HEK 293T cells (6x105 cells per 
well in 6-well plates) with 4 μg of pNL4-3 using Lipofectamine 2000 transfectant agent (Life 
Technologies; Oslo, Norway). Supernatants were collected at 48 h after transfection, 
centrifuged at 3000 g for 5 min to remove cell debris, clarified by passage through a 0.22 
μm syringe filter to remove residual cellular contaminants and frozen at -80°C until 
needed. 
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Cellular uptake of ODNs  
Human U87-CD4+-CXCR4+ and HEK 293 cell lines were independently incubated with 10 
pmol of 3’-end 32P-labeled GEM 91 (PS) or Gluc-GEM 91 (PS) at 37°C for 2, 4 and 8 h. 
After incubation, extracellular 32P-labeled oligonucleotide was removed by digestion for 2 
min with 300 U/mL of DNase I in 50 mM Tris-HCl pH 7.6, 10 mM MgCl2 and washed three 
times with phosphate-buffered saline (PBS). Cells were then trypsinized, collected in 1 mL 
of PBS and centrifuged at 1000 g for 5 min. The cell pellet was lysed with 500 mL of 10 
mM Tris-HCl pH 7.4, 150 mM NaCl and1% SDS, and centrifuged at 3000 g for 15 min. The 
supernatant was collected in microcentrifuge tubes and the ODN was precipitated by 
adding 50 µL of 5 M NaCl and 1 mL of cold 100% ethanol. After 1 h at -80°C, the solution 
was centrifuged at 12000 g for 15 min. The supernatant was removed and the pellet was 
air-dried. Samples were dissolved in 20 µL of a solution containing 10 mM Tris-HCl and 50 
mM NaCl and radioactivity was quantified using a QuickCount QC-4000/XER Benchtop 
Radioisotope Counter (Bioscan, Inc., Washington DC). Uptake was calculated as the 
proportion of the pellet-associated radioactive counts per minute (cpm) with respect to the 
total cpm input. 
 
Quantitative real-time RT-PCR 
Real-time RT-PCR assays were performed 24 h after treatment of cells with ODNs. 
Namalwa cells (2x106 cells/mL) were stimulated with 2.5 μM of GEM 91, Gluc-GEM 91 or 
the immunostimulatory CpG OD2006 (5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’) used as 
positive control. Cells were harvested 24 h after ODN treatment and total RNA was 
extracted using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. To remove potentially contaminating genomic DNA, all RNA samples were 
digested with 1 U of RNase-free RQ1 DNase at 37°C for 30 min followed by phenol-
chloroform extraction. RNA was dissolved in 30 μL of nuclease-free water and stored at -
 18
80ºC. Total RNA (1 µg) was reverse transcribed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) and random hexamers, according to the 
manufacturer’s instructions. The cDNA was used as a template for quantitative qRT-PCR 
analysis to measure the relative amount of IL-10 mRNA using iTaq Fast SYBR Green 
Supermix with ROX (Bio-Rad), in combination with the ABI 7000 sequence detection 
system (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. 
The IL-10 RT-PCR was done with primers: forward, 5′-TCGGTGATGGTCTCTTCCTC-3′ 
and reverse, 5′-CGTCGCAATAAACCGTACCT-3′ amplifying a 237-bp fragment. Gene 
expression was normalised to the GAPDH expression levels. The calibrator sample in real-
time PCR was the cDNA from untransfected Namalwa cells. Data was analysed using the 
comparative cycle threshold (Ct) method, as described.[39]  
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Figure Legends  
 
Figure 1. GEM 91 ODN. A) Sequence of GEM 91 and the targeted region in the 5’-end of 
the HIV-1 RNA genome. B) Backbone modifications and glucose molecule conjugated to 
GEM 91 ODN. 
 
Figure 2. Serum stability of ODNs. A representative polyacrylamide gel electrophoresis of 
each ODN incubated in DMEM medium supplemented with 10% FBS is shown. Incubation 
times are indicated on top. A collection of synthetic ODN of 45, 25 and 19 mer was used 
as size marker (Lane M), as indicated to the left. Gels are a representative of three 
independent experiments. 
 
Figure 3. In vitro RNase H cleavage assays. Representative autoradiograph of a 7M urea 
polyacrylamide gel resolving the RNase H-cleaved RNA fragments of the HIV-1 5’-UTR 
RNA in the presence of GEM 91 (PS), Gluc-GEM 91 (PS), GEM 91 (PO) and Gluc-GEM 
91 (PO) ODNs. Internally 32P-labelled HIV-1 5’-UTR RNA fragment was incubated to 
increasing concentrations of different antisense ODNs (indicated at the top of each lane). 
Lane control: undigested full length 32P-labelled HIV-1 5’-UTR transcript. Century marker 
(Ambion) was used as RNA size marker (lane M). 
 
Figure 4. Inhibition of viral RNA dimerisation. A constant amount of 32P-labeled HIV-1 
genomic RNA fragment 1-345 (5 nM) was incubated in high-salt conditions in the presence 
of unlabeled ODNs. The monomeric and dimeric RNA species were fractionated by 
electrophoresis on 1% native agarose gels. The dimer and monomer species are indicated 
by arrowheads to the left of the gel. Lane 1; Control monomer RNA (low-salt conditions). 
Lane 2; Control dimeric RNA (high-salt conditions) in the absence of ODN. Dimerisation 
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rate, indicated at the bottom, represents the average of two independent experiments ± 
standard deviation. Statistically significant differences were obtained with all GEM 91 ODN 
series as compared to the control (ANOVA, p < 0.001). 
 
Figure 5. Antiviral activity of glucose conjugated and unconjutated antisense ODNs. A) 
The bar graph shows the post-integrative HIV-1 inhibition obtained by measuring the 
amount of p24 antigen levels in the supernatant of U87-CD4+-CXCR4+ cell cultures 2 days 
post co-transfection with 100 ng of proviral DNA and 500 ng of the indicated ODN. B) 
U87CD4CXCR4 cells were infected with 0.4 ng of p24 HIV-1 type pNL4-3. After 3 hours, 
cells were washed and treated with 1 µM concentration ODN. Cells were incubated for 5 
days, and then p24 virus antigen expression was measured.  pLCX-25 and Random-25 
ODNs were used as negative controls. The data are the mean of three independent 
experiments, each performed in duplicate, ± standard deviation. 
 
Figure 6.  Syncytium formation inhibition by the anti HIV-1 ODNs. Microscopic view of 
U87-CD4+-CXCR4+ culture cells two days after co-transfected with plasmid pNL4-3 and 
PLCX-25, Random-25, GEM 91 (PO), Gluc-GEM 91 (PO), GEM 91 (PS) and Gluc-GEM 
91 (PS). Syncytium are indicated by arrowheads. 
 
Figure 7. Long-term ODNs antiviral activity. The bar graph shows the HIV-1 infection 
course of Jurkat cells treated with 1, 2, 4 and 8 μM of GEM 91 (PS) or Gluc-GEM 91 (PS) 
ODNs. Amount of viral particles was measured as p24 antigen in the supernatant, after 2, 
4, 6, 10, 15, 20 and 30 days. The data represent the mean of two independent 
experiments, each performed in duplicate, ± standard deviation. 
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Figure 8. Cellular ODNs uptake. HEK 293T cells were incubated with 32P-GEM 91 (PS) or 
32P-Gluc-GEM 91 (PS) at the indicated times. ODN uptake was calculated as the ratio of 
pellet-associated radioactive counts per minute (CPM) compared with total input. The 
uptake is represented by the percentage of 32P-GEM 91 (PS) or 32P-Gluc-GEM 91 (PS) 
remaining inside the cell. Data are the mean of two independent experiments which were 
carried out in duplicate ± standard deviation. 
 
Figure 9.  Induction of IL-10 mRNA in Namalwa cell cultures in the presence of ODNs. 
The bar graph shows the relative amount of IL-10 mRNA measured by RT-qPCR from 
total RNA isolated from Namalwa cell cultures immunoestimulated with GEM 91 (PS), 
Gluc-GEM 91 (PS) and OD2006 as positive control. Expression levels were normalized to 
the cellular GAPDH gene. Data represent the mean of two independent experiments ± 
standard deviation.  
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